Skip to content
stoqly

Revvity

RVTY NYSE Health Care Equipment Financials FY2016–FY2025

Revvity's revenue rose 3.7% to $2.9 billion in fiscal 2025. Its operating margin was 12.5%, down from 12.6% a year earlier. Free cash flow was $509 million, down 6.0%. It paid out $854 million in dividends and buybacks, 168% of free cash flow. The diluted share count fell 5.1%.

Last close · Oct 23, 2026

$158.77

0.9%
Value it Compare
Revenue Total sales reported in the income statement.
$2.9B
3.7% vs prior year
Operating margin Operating income as a share of revenue.
12.5%
0.1 pts
Net income Profit after all expenses, interest and tax.
$241M
10.8%
Free cash flow Cash from operations minus capital spending.
$509M
6.0%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
3.3%
0.2 pts
Market cap Last close times the latest diluted share count, so it is approximate.
$17.7B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
76.0x
On $2.09 EPS (TTM)

What Revvity does

No business description yet.

Legal name
REVVITY, INC
Fiscal year ends
December 28, 2025
Latest annual report
—
Accession · CIK
0000031791-26-000012
0000031791

Revenue and margins

Revvity had $2.9B of revenue in fiscal 2025, up 3.7% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

From fiscal 2016 to 2025, diluted EPS grew −0.3% a year. Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was $509M in fiscal 2025, 17.8% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Revvity returned $854M to shareholders in fiscal 2025, 168% of free cash flow. The diluted share count fell 5.1%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Value Revvity yourself

Change the assumptions and see what they imply per share. These are models, not forecasts or price targets — the answer depends entirely on what you put in.

Discounted cash flow

Value per share

—

Adds net cash of −$2.3B and divides by 116.6M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.

Earnings multiple

Value per share

—

Reference multiples: today 76.0x · peers 24.4x · sector 27.9x.

Balance sheet

Cash, debt and the ratios that show how comfortably Revvity can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $603M$454M$1.6B$1.2B$920M
Debt incl. finance leases $5.0B$4.4B$3.9B$3.2B$3.2B
Net debt / EBITDA 2.8x3.4x3.1x2.6x3.0x
Debt / equity 0.7x0.6x0.5x0.4x0.4x
Interest coverage 23.3x7.1x3.0x3.6x3.9x
Current ratio 2.0x2.1x2.1x3.6x1.7x
Quick ratio 1.7x1.9x1.8x3.0x1.4x
Total assets $15.0B$14.1B$13.6B$12.4B$12.2B
Total liabilities $7.9B$6.7B$5.7B$4.7B$4.9B
Shareholders' equity $7.1B$7.4B$7.9B$7.7B$7.3B
Net debt (− = net cash) $4.4B$3.9B$2.3B$2.0B$2.3B

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$6.0M

7 insiders

Of sales under plans

99%

$5.9M

DateInsiderTradeSharesPriceValueFiling
Oct 1, 2026 Anita GonzalesVP and CAO Sold plan 84 $155.48 $0.0M Form 4
Sep 21, 2026 Maxwell KrakowiakPlease See Remarks Sold plan 1,631 $144.53 $0.2M Form 4
Sep 16, 2026 Tajinder S VohraPlease See Remarks Sold plan 7,330 $140.88 $1.0M Form 4
Jul 20, 2026 Anita GonzalesVice President and CAO Sold plan 85 $109.48 $0.0M Form 4
Apr 20, 2026 Anita GonzalesVice President and CAO Sold plan 80 $92.80 $0.0M Form 4
Feb 24, 2026 Miriame VictorPlease See Remarks Sold plan 1,862 $97.13 $0.2M Form 4
Feb 23, 2026 Michelle McMurry-HeathDirector Sold 600 $97.26 $0.1M Form 4
Feb 5, 2026 Joel S GoldbergPlease See Remarks Sold plan 12,717 $100.21 $1.3M Form 4
Feb 5, 2026 Prahlad R. SinghPlease See Remarks, Director Sold plan 25,525 $100.21 $2.6M Form 4
Feb 2, 2026 Tajinder S VohraPlease See Remarks Sold plan 5,756 $104.50 $0.6M Form 4

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY23FY24FY25
Net income is positive ✓ ✓ ✓
Cash from operations is positive ✓ ✓ ✓
Return on assets rose ✓ ✕ ✕
Cash from operations exceeds net income ✕ ✓ ✓
Debt fell relative to assets ✓ ✓ ✕
Current ratio rose ✕ ✓ ✕
Share count didn't rise ✓ ✓ ✓
Gross margin rose — — —
Revenue rose relative to assets ✕ ✓ ✓
F-score 5 / 87 / 85 / 8
Accruals ratio 4.4%−2.8%−2.8%
Altman Z'' 3.704.333.86

Similar companies

Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.

CompanyMarket capGrowthOp. marginFCF marginROICP/EF-score
Revvity RVTY $17.7B 3.7% 12.5% 17.8% 3.3% 76.0x 5
Globus Medical GMED $11.2B 16.7% 16.3% 20.0% 11.0% 20.9x 9 Compare →
Insulet PODD $10.3B 30.7% 17.5% 14.0% 20.4% 27.9x 7 Compare →
AdaptHealth AHCO $819M −0.5% 2.8% 6.8% 2.1% — 4 Compare →
Bruker BRKR $8.8B 2.1% 2.0% 1.3% 0.9% — 4 Compare →

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $2.1B $2.3B $2.8B $2.9B $3.8B $3.8B $3.3B $2.8B $2.8B $2.9B
Gross profit $1.0B $1.1B $1.3B $1.4B $2.1B $2.4B $2.0B — — —
Research and development $124M $140M $194M $189M $146M $200M $222M $217M $197M $216M
Operating income $295M $296M $324M $362M $867M $1.3B $743M $301M $347M $357M
Interest expense $41.5M $43.9M $67.0M $63.6M $49.7M $54.1M $104M $98.8M $96.3M $92.2M
Pretax income $244M $297M $258M $237M $800M $1.2B $652M $183M $316M $268M
Income tax $28.4M $140M $20.2M $9.4M $170M $314M $139M $3.5M $33.1M $28.4M
Net income $234M $293M $238M $228M $728M $943M $569M $693M $270M $241M
Diluted EPS $2.12 $2.64 $2.13 $2.04 $6.49 $8.08 $4.50 $5.55 $2.20 $2.07
Diluted shares 0.11B 0.11B 0.11B 0.11B 0.11B 0.12B 0.13B 0.12B 0.12B 0.12B
Cash flow
Cash from operations $351M $289M $311M $364M $892M $1.4B $680M $91.3M $628M $583M
Capital expenditure $31.7M $39.1M $93.3M $76.3M $63.6M $86.0M $85.6M $81.4M $86.6M $73.5M
Free cash flow $319M $249M $218M $287M $829M $1.3B $594M $9.9M $542M $509M
Depreciation and amortization $100M $105M $181M $214M $202M $311M $427M $432M $428M $405M
Stock-based compensation $17.2M $25.4M $28.8M $31.5M $26.9M $29.7M $51.5M $41.4M $37.8M $22.8M
Acquisitions $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Share buybacks $152M $3.8M $57.4M $6.3M $6.9M $73.1M $80.6M $389M $370M $821M
Dividends paid $30.8M $30.8M $31.0M $31.1M $31.2M $32.4M $35.3M $35.0M $34.5M $32.8M
Dividends and buybacks $183M $34.6M $88.5M $37.4M $38.2M $105M $116M $424M $404M $854M
Balance sheet
Cash and short-term investments $359M $202M $163M $192M $387M $603M $454M $1.6B $1.2B $920M
Total debt $1.0B $2.0B $1.9B $2.1B $2.0B $5.0B $4.4B $3.9B $3.2B $3.2B
Finance lease liabilities $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Current assets $1.2B $1.2B $1.2B $1.4B $2.2B $2.4B $3.3B $3.0B $2.3B $2.2B
Current liabilities $603M $951M $772M $763M $1.7B $1.2B $1.5B $1.5B $653M $1.3B
Inventory $247M $352M $338M $357M $515M $426M $406M $428M $368M $380M
Property and equipment, net $146M $298M $319M $318M $368M $486M $483M $510M $482M $479M
Total assets $4.3B $6.1B $6.0B $6.5B $8.0B $15.0B $14.1B $13.6B $12.4B $12.2B
Total liabilities $2.1B $3.6B $3.4B $3.7B $4.2B $7.9B $6.7B $5.7B $4.7B $4.9B
Shareholders' equity $2.2B $2.5B $2.6B $2.8B $3.7B $7.1B $7.4B $7.9B $7.7B $7.3B
Margins
Gross margin 47.9% 47.6% 48.3% 48.4% 55.8% 63.6% 60.1% — — —
Operating margin 13.9% 13.1% 11.7% 12.6% 22.9% 32.9% 22.4% 10.9% 12.6% 12.5%
EBITDA margin 18.7% 17.8% 18.2% 20.0% 28.3% 41.0% 35.3% 26.6% 28.1% 26.7%
Net margin 11.1% 13.0% 8.6% 7.9% 19.2% 24.6% 17.2% 25.2% 9.8% 8.5%
FCF margin 15.1% 11.1% 7.8% 10.0% 21.9% 34.6% 17.9% 0.4% 19.7% 17.8%
Returns
Return on capital 9.1% 4.4% 6.9% 7.7% 13.6% 11.0% 5.1% 2.7% 3.1% 3.3%
Return on capital employed 8.1% 6.7% 6.3% 6.6% 14.4% 12.5% 5.6% 2.4% 2.9% 3.2%
Return on equity 11.0% 12.6% 9.4% 8.4% 22.2% 17.3% 7.8% 9.1% 3.5% 3.2%
Return on assets 5.6% 5.6% 3.9% 3.6% 10.0% 8.2% 3.9% 5.0% 2.1% 2.0%
Growth
Revenue growth 0.5% 6.7% 23.1% 3.8% 31.2% 1.2% −13.5% −17.0% 0.2% 3.7%
Net income growth 10.3% 24.9% −18.7% −4.4% 219.9% 29.6% −39.7% 21.8% −61.0% −10.8%
EPS growth 13.4% 24.5% −19.3% −4.2% 218.1% 24.5% −44.3% 23.3% −60.4% −5.9%
FCF growth 23.2% −21.8% −12.7% 31.8% 188.6% 59.9% −55.2% −98.3% 5,369.0% −6.0%
Share count change −2.7% 0.5% 0.6% −0.0% 0.5% 4.1% 8.4% −1.3% −1.6% −5.1%
Financial health
Net debt / EBITDA 1.7x 4.5x 3.4x 3.3x 1.5x 2.8x 3.4x 3.1x 2.6x 3.0x
Debt / equity 0.5x 0.8x 0.7x 0.7x 0.5x 0.7x 0.6x 0.5x 0.4x 0.4x
Interest coverage 7.1x 6.7x 4.8x 5.7x 17.5x 23.3x 7.1x 3.0x 3.6x 3.9x
Current ratio 2.0x 1.3x 1.6x 1.8x 1.4x 2.0x 2.1x 2.1x 3.6x 1.7x
Quick ratio 1.6x 0.9x 1.2x 1.3x 1.0x 1.7x 1.9x 1.8x 3.0x 1.4x
Capital allocation
Capex / revenue 1.5% 1.7% 3.4% 2.7% 1.7% 2.3% 2.6% 3.0% 3.2% 2.6%
Stock comp / revenue 0.8% 1.1% 1.0% 1.1% 0.7% 0.8% 1.6% 1.5% 1.4% 0.8%
Payouts / FCF 57.3% 13.9% 40.6% 13.0% 4.6% 8.0% 19.5% 4,279.6% 74.6% 167.6%
Quality scores
Piotroski F-score 7.0 4.0 6.0 7.0 7.0 6.0 5.0 5.0 7.0 5.0
Altman Z'' 4.0 2.6 3.1 3.2 3.6 3.0 3.5 3.7 4.3 3.9
Accruals ratio −2.8% 0.1% −1.2% −2.2% −2.3% −4.1% −0.8% 4.4% −2.8% −2.8%

Source: SEC EDGAR XBRL filings (CIK 0000031791). Data updated October 9, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open